Update shared on19 Aug 2025
Fair value Increased 10%Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth.
What's in the News
- Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.
- Fortress Biotech was dropped from the Russell 3000E Growth Benchmark.
- Fortress Biotech was dropped from the Russell 3000E Growth Index.
- Fortress Biotech was dropped from the Russell Microcap Growth Index.
- Shareholders approved the Second Amended and Restated Certificate of Incorporation to include officer exculpation.
Valuation Changes
Summary of Valuation Changes for Fortress Biotech
- The Consensus Analyst Price Target has significantly fallen from $10.00 to $8.00.
- The Future P/E for Fortress Biotech has significantly fallen from 17.14x to 9.69x.
- The Consensus Revenue Growth forecasts for Fortress Biotech has significantly risen from 49.5% per annum to 57.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.